All News

Data from the phase 2 OVARIO study showed extended progression-free survival benefit of niraparib plus bevacizumab in patients with heavily pretreated advanced ovarian cancer.

A dostarlimab triplet combination showed promise in a phase 2 study for treatment of patients with platinum-resistant ovarian cancer, according to a presentation at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer.

An update from the phase 3 ARIEL4 trial presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer supports the continued use of rucaparib in patients with BRCA-mutant relapsed advanced ovarian cancer, based on progression-free survival and response data.

Patients with newly diagnosed ovarian cancer who had interval debulking surgery and visible residual disease showed promising outcomes when treated with the PARP inhibitor niraparib, according to a post hoc analysis of a phase 3 clinical trial.

Compugen announced updated data surrounding the investigational therapeutic antibody, COM701, as monotherapy and in combination with nivolumab.

Following a prior announcement that the phase 3 KEYNOTE-775 trial met both primary end points of progression-free and overall survival benefit, data for the pembrolizumab/lenvatinib combination were presented at the Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer.

Data presented at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care found that breast pCR was predictive of nodal pCR for patients with HER2-positive and triple-negative breast cancer treated with chemotherapy.

CancerNetwork® sat down with Thomas Hutson, DO, PharmD, to discuss results of the CLEAR trial presented at the recent Genitourinary Cancers Symposium.

Based on a single-institution study, investigators were able to correlate outcomes for unresectable colorectal liver metastases with the addition of hepatic arterial infusion pump therapy to systemic therapy to the presence of a mutation in KRAS.

One year after surgery, patients aged 70 years or older experienced moderate-to-severe tiredness, poor well-being, and lack of appetite.

A selective internal radiation therapy from Boston Scientific Corporation, TheraSphere Y-90 Glass Microspheres, was granted FDA approval for the treatment of unresectable hepatocellular carcinoma.

Exelixis recently announced that cabozantinib received a breakthrough therapy designation from the FDA based on data from the COSMIC-311 trial for the treatment of differentiated thyroid cancer.

A novel imaging technology was cleared by the FDA to detect polyps with neoplastic potential during conduct of colonoscopy that aligns with pathological assessment with greater than 90% predictive ability.

Recently reported results from the ongoing phase 1 TUNINTIL trial of the oncolytic virus TILT-123 show safety of this approach.

“As the first AML trial to use MRD negative CR as a primary endpoint, our trial is breaking new ground that may help deliver effective, targeted therapies more expeditiously to patients living with this devastating disease,” Bischofberger said.

CancerNetwork® sat down with Conor E. Steuer, MD, to discuss a recently published prospective study which found a high rate of smoking reduction and cessation in patients with non–small cell lung cancer.

The FDA accepted a new drug application for belzutifan to treat von Hippel-Lindau disease¬–associated renal cell carcinoma and granted it priority review based on response rate results from a phase 2 trial.

The use of next-generation imaging, like PSMA PET, has been shown to be superior compared with conventional imaging and may become a homestay in prostate cancer care in the future.

The latest episode of the podcast dissects a piece of original research from the Journal ONCOLOGY focusing on the impact of treatment refusal on patients with small cell lung cancer.

Based on promising responses seen across several clinical trials of poziotinib in patients with non–small cell lung cancer and exon 20 mutations in HER2, the FDA granted the therapy fast track designation.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about breast cancer, prostate cancer, and urothelial cancer.

Promising overall survival results lead to an early stop to a phase 3 trial of cemiplimab versus chemotherapy in relapsed/refractory cervical cancer, according to the drug’s developer.

The new combination treatment of ublituximab plus ibrutinib resulted in a higher overall response rate and a tolerable safety profile for patients with relapsed or refractory high-risk CLL.

Combination chemotherapy treatment followed by individualized PET4-guided therapy allowed some patients with unfavorable Hodgkin lymphoma to forego radiotherapy while maintaining efficacy.

A bevacizumab-plus-chemotherapy combination improved progression-free survival for a cohort of patients with recurrent platinum-sensitive ovarian cancer, suggesting the potential for a future therapeutic path in clinical practice.

These data in Nature Communications found that Black men may derive survival benefits from immunotherapy treatment.

Leonard G. Gomella, MD, FACS, detailed updated information regarding the standard of care and overall management of patients with non-muscle invasive bladder cancer at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.

Scott G. Hubosky, MD, of Jefferson University Hospitals, discussed methods of treating patients with upper tract urothelial carcinoma at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.

CancerNetwork® sat down with Trevor J. Pugh, PhD, to discuss a novel protocol for detecting mismatch repair deficiency.

Indications for pembrolizumab, nivolumab, and atezolizumab are set for examination under the FDA’s Oncologic Drugs Advisory Committee for indications granted accelerated approval in breast, urothelial, gastric, and liver cancers.